| 3i |
| 4SC |
| Abingworth |
| ABN AMRO Rothschild |
| Accelsiors Group |
| Advent Venture Partners |
| AIM |
| Albany Venture Managers |
| Alice Ventures |
| Alpha Biologics |
| Alta Partners |
| Apax |
| Apposite Capital |
| Astex Therapeutics |
| Atila Ventures |
| Atlas Venture |
| ATPBio |
| Avlar BioVentures |
| BankInvest |
| Bayhill Therapeutics |
| BB Biotech |
| BioCentury |
| BioDiem |
| Bio-M |
| BioRexis Pharmaceutical Corporation |
| BioScience Managers |
| Borean Pharma |
| Breslin |
| Bristol-Myers Squibb |
| BTG International |
| Cambridge Enterprise Seed Funds |
| Canaccord Adams |
| Capitalinq |
| Capsant Neurotechnologies |
| Cavendish Asset Management |
| Celldex Therapeutics |
| Cellectis |
| Celtic Biotech |
| CeNeS Pharmaceuticals |
| Citigate Dewe Rogerson |
| Clear Capital |
| Clubb Capital |
| Coller Capital |
| Credit Agricole Private Equity |
| Credit Suisse |
| Credit Suisse First Boston |
| Deloitte & Touche |
| Destiny Pharma |
| Deutsche Bank |
| Dootech |
| Dunhaw Capital |
| DVC Deutsche Venture Capital |
| DyoDelta Biosciences |
| Earlybird Venture Capital |
| Eden Financial |
| Edison Investment Research |
| Equity Development |
| European Venture Partners |
| Evolution Securities |
| Ferghana Partners |
| Fondsfinans |
| Fortis Private Investment Management |
| immatics biotechnologies |
| Index Ventures |
| InnovationsKapital |
| Innovator Capital |
| Inverseon |
| ITI Life Sciences |
| Jefferies |
| Jupiter Asset Management |
| KBC Peel Hunt |
| KBC Private Equity |
| KDS Associates |
| Larpent Newton |
| LEK Consulting |
| Life Science & Financing Advisory |
| Magdalen College, Oxford University |
| Merger Market |
| Merton College, Oxford University |
| Morgan Lewis |
| Morgan Stanley |
| MorphoSys |
| MVM Life Science Partners |
| Nabarro Wells |
| Newton Investment Management |
| Nextech Venture |
| Nomura Code Securities |
| Nomura International |
| Nordic unquote |
| Northbank Communications |
| Novartis Venture Fund |
| Novo |
| NRW Bank |
| Numis Securities |
| NW Brown Capital Partners |
| Oakes, Lyman & Co |
| Objective Capital |
| Omega Fund |
| Orexo |
| Osprey Capital Partners |
| Oxford Finance |
| Oxford Genome Sciences |
| OXiGENE |
| Panmure Gordon |
| Paul Capital Partners |
| Peptech |
| Pharmaceutical Profiles |
| PIramed |
| Plethora Solutions |
| PolyMedix |
| PowderMed |
| Privateq Advisors |
| ProMetic Biosciences |
| Protox Therapeutics |
| pSivida |
| Quiddity Media |
| R & D Focus, IMS Health |
| Reabourne Technology Investment Management |
| ReNeuron |
| Santaris Pharma |
| Scottish Financial Enterprise |
| Scottish Widows Investment Partnership |
| Seymour Pierce |
| SG Securities |
| Sitka Limited |
| Sofinnova Partners |
| South East Growth Fund |
| Sowerby International |
| SPEF Venture |
| SV Life Sciences |
| Symphogen |
| Teather & Greenwood |
| The Hogarth Partnership |
| The Rainbow Seed Fund |
| TVM Capital |
| Urigen |
| Utek |
| Venture Valuation |
| Wales Fund Managers |
| Wilshire Private Markets |
| WOCP (The Worldwide Organisation for
Collaborations in the Pharmaceutical Industry) |
| Wood Mackenzie |